Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103(9):1916–1924. https://doi.org/10.1002/cncr.20983

Article  PubMed  Google Scholar 

Crawford J et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6(2):109–118. https://doi.org/10.6004/jnccn.2008.0012

Article  PubMed  Google Scholar 

Jolis L et al (2013) Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study. Eur J Cancer Care (Engl) 22(4):513–521. https://doi.org/10.1111/ecc.12057

Article  CAS  PubMed  Google Scholar 

Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH (2015) Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 11(1):47–54. https://doi.org/10.1200/JOP.2014.001492

Article  PubMed  Google Scholar 

Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266. https://doi.org/10.1002/cncr.21847

Article  PubMed  Google Scholar 

Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100(2):228–237. https://doi.org/10.1002/cncr.11882

Article  PubMed  Google Scholar 

Khan S, Dhadda A, Fyfe D, Sundar S (2008) Impact of neutropenia on delivering planned chemotherapy for solid tumours. Eur J Cancer Care (Engl) 17(1):19–25. https://doi.org/10.1111/j.1365-2354.2007.00797.x

Article  CAS  PubMed  Google Scholar 

Mohanlal R, Ogenstad S, Lyman GH, Huang L, Blayney DW (2023) Grade 4 neutropenia frequency as a binary risk predictor for adverse clinical consequences of chemotherapy-induced neutropenia: a meta-analysis. Cancer Invest 41(4):369–378. https://doi.org/10.1080/07357907.2023.2179064

Article  CAS  PubMed  Google Scholar 

Nissen-Druey C (1989) Human recombinant hemopoietic growth factors G-CSF and GM-CSF: first results of clinical trials. Nouv Rev Fr Hematol 31(2):99–101. Accessed: Mar. 03, 2023. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/2475852/

Cupp J, Culakova E, Poniewierski MS, Dale DC, Lyman GH, Crawford J (2018) Analysis of factors associated with in-hospital mortality in lung cancer chemotherapy patients with neutropenia. Clin Lung Cancer 19(2):e163–e169. https://doi.org/10.1016/j.cllc.2017.10.013

Article  PubMed  Google Scholar 

Boccia R, Glaspy J, Crawford J, Aapro M (2022) Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist 27(8):625–636. https://doi.org/10.1093/oncolo/oyac074

Article  PubMed  PubMed Central  Google Scholar 

Lalami Y, Klastersky J (2017) Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol 120(October):163–179. https://doi.org/10.1016/j.critrevonc.2017.11.005

Article  PubMed  Google Scholar 

Strojnik K, Mahkovic-Hergouth K, Novakovic BJ, Seruga B (2016) Outcome of severe infections in afebrile neutropenic cancer patients. Radiol Oncol 50(4):442–448. https://doi.org/10.1515/raon-2016-0011

Article  PubMed  PubMed Central  Google Scholar 

Sickles EA, Greene WH, Wiernik PH (1975) Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135(5):715–719

Article  CAS  PubMed  Google Scholar 

Moro K et al (2022) Advanced stage is a risk for severe neutropenia in breast cancer patients undergoing neoadjuvant adriamycin/cyclophosphamide/docetaxel chemotherapy. World J Oncol 13(6):379–386. https://doi.org/10.14740/wjon1530

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao X et al (2020) Predicting risk of chemotherapy-induced severe neutropenia: a pooled analysis in individual patients data with advanced lung cancer. Lung Cancer 141:14–20. https://doi.org/10.1016/j.lungcan.2020.01.004

Article  PubMed  Google Scholar 

Zou W, Xu N-L (2021) Development and internal validation of a nomogram used to predict chemotherapy-induced neutropenia in non-small cell lung cancer patients: a retrospective cohort study. Cancer Manag Res 13:2797–2804. https://doi.org/10.2147/CMAR.S302722

Article  PubMed  PubMed Central  Google Scholar 

Lalami Y et al (2006) Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors ? A retrospective analysis. Ann Oncol 17(3):507–514. https://doi.org/10.1093/annonc/mdj092

Article  CAS  PubMed  Google Scholar 

Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90(3):190–199. https://doi.org/10.1016/j.critrevonc.2013.12.006

Article  PubMed  Google Scholar 

Klastersky J et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol Off J Am Soc Clin Oncol 18(16):3038–3051. https://doi.org/10.1200/JCO.2000.18.16.3038

Article  CAS  Google Scholar 

Lee YM, Lang D, Lockwood C (2012) Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis. JBI Libr Syst Rev 10(40):2593–2657. https://doi.org/10.11124/jbisrir-2012-31

Article  PubMed  Google Scholar 

J. Klastersky and M. Paesmans, (2013) The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 21(5):1487–1495. https://doi.org/10.1007/s00520-013-1758-y

Zimmer AJ, Freifeld AG (2019) Optimal management of neutropenic fever in patients with cancer. J Oncol Pract 15(1):19–24. https://doi.org/10.1200/JOP.18.00269

Article  PubMed  Google Scholar 

Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, Ozer H (2005) Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther 3(1):36–46. https://doi.org/10.3816/SCT.2005.n.023

Article  CAS  PubMed  Google Scholar 

Alshari O, Al Zu’bi YO, Al Sharie AH, Wafai FH, Aleshawi AJ, Atawneh FH, Obeidat HA, Daoud MN, Khrais MZ, Albals D, Tubaishat F (2021) Evaluating the prognostic role of monocytopenia in chemotherapy-induced febrile neutropenia patients treated with granulocyte colony-stimulating factor. Ther Clin Risk Manag 7(17):963–973. https://doi.org/10.2147/TCRM.S318370

Article  Google Scholar 

Wang C, Heldermon CD, Vouri SM et al (2021) Trends in use of granulocyte colony-stimulating factor following introduction of biosimilars among adults with cancer and commercial or medicare insurance from 2014 to 2019. JAMA Netw Open 4(11):e2133474. https://doi.org/10.1001/jamanetworkopen.2021.33474

Article  PubMed  PubMed Central  Google Scholar 

Falandry C, Campone M, Cartron G, Guerin D, Freyer G (2010) Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer 46(13):2389–2398. https://doi.org/10.1016/j.ejca.2010.04.031

Article  CAS  PubMed  Google Scholar 

Nesher L, Rolston KV (2014) The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 42(1):5–13. https://doi.org/10.1007/s15010-013-0525-9

Article  CAS  PubMed  Google Scholar 

Marshall W, Campbell G, Knight T, Al-Sayed T, Cooksley T (2020) Emergency ambulatory management of low-risk febrile neutropenia: multinational association for supportive care in cancer fits-real-world experience from a UK cancer center. J Emerg Med 58(3):444–448. https://doi.org/10.1016/j.jemermed.2019.09.032

Article  PubMed  Google Scholar 

Forcano-Queralt E, Lemes-Quintana C, Orozco-Beltrán D (2023) Ambulatory management of low-risk febrile neutropenia in adult oncological patients. Systematic review. Support Care Cancer 31(12):1–10. https://doi.org/10.1007/s00520-023-08065-y

Article  Google Scholar